NEW YORK – CRISPR QC has raised $10 million in a Series A financing round, the company's lead investor said on Friday.
The San Diego-based startup has developed a platform to analyze the quality of CRISPR/Cas9 gene editing. The technology relies on a biosensor called the CRISPR-Chip that can directly measure CRISPR activity.
Xcellerant Ventures, based in Phoenix, led the round and is helping the company as a board member with strategic decisions. It did not disclose any other investors. As part of the new funding, CRISPR QC has opened an office in Scottsdale, Arizona.
CRISPR QC's new financing follows $1.6 million in seed funding the company raised a year ago.